These mutations have important clinical significance since mutated BRAF protein is active as a monomer instead of dimer and the monomer conformation is the target for the binding of BRAF inhibitors, such as vemurafenib, dabrafenib and encorafenib, used in melanoma therapy (Czarnecka et al., 2020). The gene discussed is BRAF; the disease is melanoma.